Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.72 |
| ▸ | RXRB | P28702 | 4/20 | 0.72 |
| ▸ | RXRG | P48443 | 4/20 | 0.72 |
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.71 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550855 | 0.89 | RXRA (0.61) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL10323581 | 0.89 | RXRA (0.61) | RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL1437991 | 0.89 | RXRA (0.61) | RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL849231 | 0.89 | RXRA (0.72) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL79430 | 0.88 | RXRA (0.63) | RXRARXRBRXRGMRGPRX4KMT2A | |
| SCHEMBL20897436 | 0.87 | MRGPRX4 (0.82) | RXRARXRBRXRGMRGPRX4NR4A2 | |
| SCHEMBL3178999 | 0.87 | RXRA (0.56) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL2950475 | 0.87 | RXRA (0.59) | RXRARXRBRXRGMRGPRX4MEN1 | |
| SCHEMBL3901919 | 0.87 | MRGPRX4 (0.69) | RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL1437962 | 0.87 | RXRA (0.59) | RXRARXRBRXRGMRGPRX4PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020157189-A1 | 1,2,4-TRIAZIN-6(1H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| US-10611727-B2 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | UNIVERSITAT DE BARCELONA (ES) | 2020-04-07 | — | — | US | disclosed |
| US-10611727-B2 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | UNIVERSITAT DE BARCELONA (ES) | 2020-04-07 | — | — | US | disclosed |
| US-20190084927-A1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | UNIVERSITAT DE BARCELONA (ES) | 2019-03-21 | — | — | US | disclosed |
| US-20190084927-A1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | UNIVERSITAT DE BARCELONA (ES) | 2019-03-21 | — | — | US | disclosed |
| US-10125097-B2 | 1- [1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | UNIVERSITAT DE BARCELONA (ES) | 2018-11-13 | — | — | US | disclosed |
| EP-2917209-B1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | UNIV BARCELONA (ES) | 2017-02-08 | — | — | EP | disclosed |
| EP-2917209-B1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | UNIV BARCELONA (ES) | 2017-02-08 | — | — | EP | disclosed |
| US-20160168088-A1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | IPROTEOS S,L, (ES) | 2016-06-16 | — | — | US | disclosed |
| US-20160168088-A1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | IPROTEOS S,L, (ES) | 2016-06-16 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016674-A1 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| US-7098343-B2 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STERIX, LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060142360-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2006-06-29 | — | — | US | disclosed |
| CN-1599728-A | Sulfamate-containing 1,2, 4-triazole derivatives as aromatase inhibitors | STERIX LTD (GB) | 2005-03-23 | — | — | CN | disclosed |
| EP-1446388-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | RICHTER GEDEON NYRT. (HU) | 2004-01-29 | — | — | US | disclosed |
| WO-2003045925-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | RXRA 2518/4885RXRB 2305/4885RXRG 2300/4885 |
| US-20190084927-A1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | BDNF, GRIN1, NLN | RXRA 3080/4885RXRB 2762/4885RXRG 3404/4885 |
| US-10611727-B2 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | BDNF, GRIN1, NLN | RXRA 3080/4885RXRB 2762/4885RXRG 3404/4885 |
| US-10125097-B2 | 1- [1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | BDNF, GRIN2A, NLN | RXRA 2208/4885RXRB 2032/4885RXRG 2460/4885 |
| US-20160168088-A1 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | BDNF, GRIN2A, NLN | RXRA 2208/4885RXRB 2032/4885RXRG 2460/4885 |
| US-20060142360-A1 | Compound | QPCT, SQOR, SDHA | RXRA 1453/4885RXRB 1128/4885RXRG 1041/4885 |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STS, CYP21A2, SULT1E1 | RXRA 2296/4885RXRB 2073/4885RXRG 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.